Free Trial

Altimmune (ALT) News Today

Altimmune logo
$4.95 -0.02 (-0.32%)
As of 10:24 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Altimmune, Inc. stock logo
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued
Altimmune, Inc. stock logo
Altimmune, Inc. (NASDAQ:ALT) Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. lessened its holdings in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,431,612 shares of the company's stock after selling 552,246 shares d
Altimmune's US$42m Market Cap Fall Books Insider Losses
Altimmune management to meet with Piper Sandler
Altimmune, Inc. stock logo
Altimmune (NASDAQ:ALT) Earns "Buy" Rating from HC Wainwright
HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday.
Altimmune, Inc. stock logo
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recomm
Altimmune, Inc. stock logo
Altimmune (NASDAQ:ALT) Receives "Buy" Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research report on Tuesday.
Altimmune, Inc. stock logo
William Blair Reaffirms "Market Perform" Rating for Altimmune (NASDAQ:ALT)
William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday.
Altimmune, Inc. stock logo
Altimmune Sees Unusually High Options Volume (NASDAQ:ALT)
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of unusually large options trading activity on Friday. Investors purchased 25,356 call options on the company. This represents an increase of approximately 199% compared to the typical volume of 8,475 call options.
Altimmune, Inc. stock logo
Insider Buying: Altimmune, Inc. (NASDAQ:ALT) CFO Purchases 10,000 Shares of Stock
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CFO Gregory L. Weaver bought 10,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were bought at an average price of $5.20 per share, with a total value of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Stifel Nicolaus Keeps Their Buy Rating on Altimmune (ALT)
Piper Sandler Reaffirms Their Buy Rating on Altimmune (ALT)
Altimmune (ALT) Gets a Hold from William Blair
Altimmune, Inc. stock logo
What is HC Wainwright's Estimate for Altimmune Q2 Earnings?
Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2025 EPS estimates for shares of Altimmune in a report issued on Monday, March 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.34) per share for the quarter,
Altimmune, Inc. stock logo
HC Wainwright Has Negative View of Altimmune FY2029 Earnings
Altimmune, Inc. (NASDAQ:ALT - Free Report) - Stock analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $1.2
Altimmune to Host Virtual R&D Day on March 13, 2025
Altimmune (ALT) Initiated with a Hold at William Blair
Altimmune, Inc. stock logo
B. Riley Brokers Increase Earnings Estimates for Altimmune
Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities research analysts at B. Riley lifted their FY2025 EPS estimates for Altimmune in a report released on Friday, February 28th. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.86 per share for the year, up from their pri
Altimmune, Inc. stock logo
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research report on Monday.
Altimmune, Inc. stock logo
B. Riley Has Optimistic Outlook of Altimmune FY2025 Earnings
Altimmune, Inc. (NASDAQ:ALT - Free Report) - Stock analysts at B. Riley upped their FY2025 earnings estimates for shares of Altimmune in a research report issued to clients and investors on Friday, February 28th. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.86 per sha
Altimmune, Inc. stock logo
William Blair Begins Coverage on Altimmune (NASDAQ:ALT)
William Blair initiated coverage on shares of Altimmune in a research note on Friday. They set a "market perform" rating for the company.
Altimmune, Inc. stock logo
Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPS
Altimmune (NASDAQ:ALT - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%.
Q4 2024 Altimmune Inc Earnings Call
Altimmune initiated with a Market Perform at William Blair
Altimmune files $400M mixed securities shelf
Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript
Altimmune, Inc. stock logo
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Buy" from Analysts
Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given an average recommendation of "Buy" by the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has
Altimmune appoints Teri Lawver, Jerry Durso to board
Altimmune, Inc. stock logo
Altimmune (ALT) to Release Earnings on Thursday
Altimmune (NASDAQ:ALT) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.
Altimmune, Inc. stock logo
Altimmune (NASDAQ:ALT) Shares Up 8.7% - Time to Buy?
Altimmune (NASDAQ:ALT) Trading 8.7% Higher - Here's Why
Get Altimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.

ALT Media Mentions By Week

ALT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALT
News Sentiment

0.67

0.72

Average
Medical
News Sentiment

ALT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALT Articles
This Week

2

8

ALT Articles
Average Week

Get Altimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ALT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners